309 related articles for article (PubMed ID: 15452548)
21. Molecular modeling approaches in the discovery of new drugs for anti-cancer therapy: the investigation of p53-MDM2 interaction and its inhibition by small molecules.
Lauria A; Tutone M; Ippolito M; Pantano L; Almerico AM
Curr Med Chem; 2010; 17(28):3142-54. PubMed ID: 20666726
[TBL] [Abstract][Full Text] [Related]
22. 1,4-Benzodiazepine-2,5-diones as small molecule antagonists of the HDM2-p53 interaction: discovery and SAR.
Parks DJ; Lafrance LV; Calvo RR; Milkiewicz KL; Gupta V; Lattanze J; Ramachandren K; Carver TE; Petrella EC; Cummings MD; Maguire D; Grasberger BL; Lu T
Bioorg Med Chem Lett; 2005 Feb; 15(3):765-70. PubMed ID: 15664854
[TBL] [Abstract][Full Text] [Related]
23. HDM2 and HDMX Proteins in Human Cancer.
Hároníková L; Vojtěšek B
Klin Onkol; 2018; 31(Suppl 2):63-70. PubMed ID: 31023026
[TBL] [Abstract][Full Text] [Related]
24. Turning the key on p53.
Lane DP; Fischer PM
Nature; 2004 Feb; 427(6977):789-90. PubMed ID: 14985740
[No Abstract] [Full Text] [Related]
25. Functional analysis and consequences of Mdm2 E3 ligase inhibition in human tumor cells.
Wade M; Li YC; Matani AS; Braun SM; Milanesi F; Rodewald LW; Wahl GM
Oncogene; 2012 Nov; 31(45):4789-97. PubMed ID: 22266850
[TBL] [Abstract][Full Text] [Related]
26. Fluorescence polarization assay and inhibitor design for MDM2/p53 interaction.
Zhang R; Mayhood T; Lipari P; Wang Y; Durkin J; Syto R; Gesell J; McNemar C; Windsor W
Anal Biochem; 2004 Aug; 331(1):138-46. PubMed ID: 15246006
[TBL] [Abstract][Full Text] [Related]
27. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
Hu B; Gilkes DM; Chen J
Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
[TBL] [Abstract][Full Text] [Related]
28. The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53.
Higashitsuji H; Higashitsuji H; Itoh K; Sakurai T; Nagao T; Sumitomo Y; Masuda T; Dawson S; Shimada Y; Mayer RJ; Fujita J
Cancer Cell; 2005 Jul; 8(1):75-87. PubMed ID: 16023600
[TBL] [Abstract][Full Text] [Related]
29. Molecular basis for the inhibition of p53 by Mdmx.
Popowicz GM; Czarna A; Rothweiler U; Szwagierczak A; Krajewski M; Weber L; Holak TA
Cell Cycle; 2007 Oct; 6(19):2386-92. PubMed ID: 17938582
[TBL] [Abstract][Full Text] [Related]
30. Targeting the MDM2/MDM4 interaction interface as a promising approach for p53 reactivation therapy.
Pellegrino M; Mancini F; Lucà R; Coletti A; Giacchè N; Manni I; Arisi I; Florenzano F; Teveroni E; Buttarelli M; Fici L; Brandi R; Bruno T; Fanciulli M; D'Onofrio M; Piaggio G; Pellicciari R; Pontecorvi A; Marine JC; Macchiarulo A; Moretti F
Cancer Res; 2015 Nov; 75(21):4560-72. PubMed ID: 26359458
[TBL] [Abstract][Full Text] [Related]
31. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
[TBL] [Abstract][Full Text] [Related]
32. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.
Tovar C; Graves B; Packman K; Filipovic Z; Higgins B; Xia M; Tardell C; Garrido R; Lee E; Kolinsky K; To KH; Linn M; Podlaski F; Wovkulich P; Vu B; Vassilev LT
Cancer Res; 2013 Apr; 73(8):2587-97. PubMed ID: 23400593
[TBL] [Abstract][Full Text] [Related]
33. MDM2 oncogene as a novel target for human cancer therapy.
Zhang ; Wang H
Curr Pharm Des; 2000 Mar; 6(4):393-416. PubMed ID: 10788589
[TBL] [Abstract][Full Text] [Related]
34. p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding.
Midgley CA; Lane DP
Oncogene; 1997 Sep; 15(10):1179-89. PubMed ID: 9294611
[TBL] [Abstract][Full Text] [Related]
35. MDM2 interaction with nuclear corepressor KAP1 contributes to p53 inactivation.
Wang C; Ivanov A; Chen L; Fredericks WJ; Seto E; Rauscher FJ; Chen J
EMBO J; 2005 Sep; 24(18):3279-90. PubMed ID: 16107876
[TBL] [Abstract][Full Text] [Related]
36. A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines.
Chène P; Fuchs J; Bohn J; García-Echeverría C; Furet P; Fabbro D
J Mol Biol; 2000 May; 299(1):245-53. PubMed ID: 10860736
[TBL] [Abstract][Full Text] [Related]
37. Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be Addressed.
Zanjirband M; Rahgozar S
Curr Drug Targets; 2019; 20(11):1091-1111. PubMed ID: 30947669
[TBL] [Abstract][Full Text] [Related]
38. Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms.
Wang H; Nan L; Yu D; Lindsey JR; Agrawal S; Zhang R
Mol Med; 2002 Apr; 8(4):185-99. PubMed ID: 12149568
[TBL] [Abstract][Full Text] [Related]
39. Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy.
Li Q; Lozano G
Clin Cancer Res; 2013 Jan; 19(1):34-41. PubMed ID: 23262034
[TBL] [Abstract][Full Text] [Related]
40. In vivo activation of the p53 tumor suppressor pathway by an engineered cyclotide.
Ji Y; Majumder S; Millard M; Borra R; Bi T; Elnagar AY; Neamati N; Shekhtman A; Camarero JA
J Am Chem Soc; 2013 Aug; 135(31):11623-11633. PubMed ID: 23848581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
